Abstract
Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessment and treatment of dually diagnosed patients has evolved over the last twenty years. To date, the strongest evidence for effective management of dual diagnosis patients has been utilization of integrated treatment services, which combines both mental health and substance abuse treatments concurrently. Strategies commonly used include a combination of pharmacological treatment, intensive case management, motivational interviewing, individual and group psychotherapy, and family participation. This chapter summarizes the treatment options available for this population.
Keywords: substance abuse and schizophrenic population, effective treatment of dual diagnosis patients
Current Pharmaceutical Design
Title: Treatment of Patients with Schizophrenia and Substance Abuse Disorders
Volume: 10 Issue: 18
Author(s): John Tsuang and Timothy W. Fong
Affiliation:
Keywords: substance abuse and schizophrenic population, effective treatment of dual diagnosis patients
Abstract: Approximately half of patients with schizophrenia have a lifetime diagnosis of substance abuse disorders. These dual diagnosis patients are more likely to have poorer outcomes, including more severe psychiatric symptoms with increased hospitalizations, higher utilization of services and frequent homelessness. Assessment and treatment of dually diagnosed patients has evolved over the last twenty years. To date, the strongest evidence for effective management of dual diagnosis patients has been utilization of integrated treatment services, which combines both mental health and substance abuse treatments concurrently. Strategies commonly used include a combination of pharmacological treatment, intensive case management, motivational interviewing, individual and group psychotherapy, and family participation. This chapter summarizes the treatment options available for this population.
Export Options
About this article
Cite this article as:
Tsuang John and Fong W. Timothy, Treatment of Patients with Schizophrenia and Substance Abuse Disorders, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384114
DOI https://dx.doi.org/10.2174/1381612043384114 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rhinosinusitis in the Pediatric Patient with Cystic Fibrosis
Current Pediatric Reviews Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies
Current Pharmaceutical Design Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide
Current Protein & Peptide Science Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Pain in Patients with Parkinson’s Disease; A Pain-related Evoked Potential Study
Neuroscience and Biomedical Engineering (Discontinued) Current Status of Antipsychotic Treatment
Current Drug Targets - CNS & Neurological Disorders Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Behavioural Sensitisation During Dopamine Replacement Therapy in Parkinsons Disease is Reminiscent of the Addicted Brain
Current Topics in Medicinal Chemistry PET Imaging in Parkinsons Disease
Current Medical Imaging Bronchiolar Disorders In Childhood
Current Pediatric Reviews Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Data Visualization and Feature Selection Methods in Gel-based Proteomics
Current Protein & Peptide Science Clinical Management of Arrhythmogenic Right Ventricular Cardiomyopathy: An Update
Current Pharmaceutical Design The Effects of Nanoencapsulated Curcumin-Fe3O4 on Proliferation and hTERT Gene Expression in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Connecting Parkinsons Disease and Drug Addiction: Common Players Reveal Unexpected Disease Connections and Novel Therapeutic Approaches
Current Pharmaceutical Design Central Serotonin2C Receptor: From Physiology to Pathology
Current Topics in Medicinal Chemistry Pediatric Catatonia: Updating An Old Syndrome in Young People
Current Psychiatry Reviews Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
Current Genomics Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Novel Potential Therapeutics for Schizophrenia: Focus on the Modulation of Metabotropic Glutamate Receptor Function
Current Neuropharmacology